Extremely low-dose vigabatrin for West syndrome with tuberous sclerosis

Naomi Fukuyo, Yuko Sato, Yosuke Kakisaka, Wakaba Endo, Yuki Kubota, Atsuo Kikuchi, Tomoko Kobayashi, Kazuhiro Haginoya, Mitsugu Uematsu, Yurika Numata, Hiroshi Doi, Masato Mori, Hitoshi Osaka, Shigeo Kure

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Treatment of west syndrome in patients with tuberous sclerosis, the relevant effective period and doses of vigabatrin (VGB) to avoid serious side effects still needs further investigation. We report on a Japanese girl who showed good results with a very low dose of VGB. Tonic spasms appeared at 5 mo of age. Adrenocorticotropic hormone therapy resulted in incomplete seizure control. VGB at the lowest practical dose (30 mg/kg/d) showed complete control after 3 d. With reduction of the dose to 10 mg/kg/d, side effects such as hyperactivity, irritability, and sleep disturbances improved. She was seizure-free for the next 6 mo with an improved developmental quotient. Ophthalmological evaluation revealed no abnormality. The present case illustrates that low-dose VGB therapy (10 mg/kg/d) has fewer side effects and may bring prompt seizure control in west syndrome with tuberous sclerosis.

Original languageEnglish
Pages (from-to)255-258
Number of pages4
JournalJournal of Pediatric Epilepsy
Issue number4
Publication statusPublished - 2013


  • Infantile spasms
  • Tuberous screlosis complex
  • Vigabatrin
  • West syndrome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology


Dive into the research topics of 'Extremely low-dose vigabatrin for West syndrome with tuberous sclerosis'. Together they form a unique fingerprint.

Cite this